Public Input Sought On CDC’s 5-Year Plan for ME/CFS Research

I received an email from the CFIDS Association on two upcoming public meetings that are to be held to discuss the CDC’s 5-year plan for ME/CFS research.  If you would like to attend, or just want to attend and give public testimony, here is the date, time and contact information:

When:  April 27, 2009 from 1:00 p.m. until 5:00 p.m.
Where:   U.S. Centers for Disease Control & Prevention (CDC) in Atlanta, GA
Deadline for action:  April 22, 2009
Respond toCFSResearchPlan@cdc.gov

Members of the public are encouraged to attend and can register to give public testimony or can submit comments in writing. The CFIDS Association of America will be represented by president & CEO Kim McCleary. Advocates who care about or are concerned about any aspect of the nation’s public health agency response to CFS are urged to participate in person or through written comments.

 

 Federal CFS Advisory Committee (CFSAC)

2-Day Meeting

When:  May 27-28, 2009
Where:  Department of Health and Human Services (DHHS) in Washington, D.C.
Deadline for Action:  May 22, 2009
Respond to:  (202) 690-7650
 

The CFSAC brings together representatives of five federal agencies with CFS programs and 11 appointed members of the public. Members of the public are welcome to attend and hear the committee dialogue. Public testimony is heard from those who have registered to deliver comments of up to 5 minutes. The meeting notice does not state whether testimony can be submitted on videotape or given by phone, but both have been permitted in the past.

The CFIDS Association has provided the following links you can review:

CDC Website

Report on CDC research and Association testimony

CFIDS Association Advocacy Alert & Response Form

CFSAC web site

Federal Register notice of the meeting (published April 6)

Past meeting reports from the Association

If you liked this article, please share.
Share on Facebook0Tweet about this on TwitterShare on Google+0Share on StumbleUpon0Email this to someone

Join the Discussion.

We'd love to hear from you - leave a comment below

*